Jardimet 5/500mg Tablet is an anti-diabetic medication. It contains a combination of empagliflozin and metformin as active substances. Jardimet 5/500mg Tablet is used for the management of type 2 diabetes in adults along with diet and exercise. Type 2 diabetes is a condition where your pancreas does not make enough insulin to effectively control the blood sugar level and your body is unable to use its own insulin effectively. This medicine works by lowering the blood sugar level. Take Jardimet 5/500mg tablet in the exact dose and duration as prescribed by your doctor. Before starting this medicine, inform your doctor if you are pregnant/breastfeeding and about your complete medical history. It is important to make certain lifestyle changes like having a balanced diet and regular exercise along with this medicine to help to manage blood sugar levels better.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Jardimet 5/500mg Tablet is a combination medication containing Empagliflozin and Metformin, which are antidiabetic agents. It is prescribed for the treatment of type 2 diabetes mellitus in adults who have not responded well to metformin alone or in combination with other antidiabetic medications. It can also be used with other medicines, including insulin, to better control blood sugar levels.
Type 2 diabetes is a chronic condition characterized by insufficient insulin production or reduced insulin effectiveness. Symptoms may include frequent urination, excessive thirst, increased hunger, fatigue, and blurred vision.
In addition to taking Jardimet 5/500mg Tablet as prescribed, it is important to follow a regular exercise routine and adhere to a recommended diet plan for optimal results. Alcohol consumption should be avoided during treatment, as it can worsen the existing condition.
If you experience conditions associated with dehydration, such as vomiting, diarrhea, fever, heat exposure, or decreased fluid intake, it may be necessary to temporarily discontinue Jardimet 5/500mg Tablet. Your kidney function will be monitored by your doctor at least once a year, or more frequently if you are elderly.
For diabetic patients, it is advised to regularly check their feet and follow any additional foot care instructions given by their doctor. Jardimet 5/500mg Tablet is generally not recommended for use in pregnant or breastfeeding women, including children and adolescents under 18 years of age, due to limited safety data.
The most common side effects of Jardimet 5/500mg Tablet include hypoglycemia (low blood sugar), nausea, vomiting, diarrhea, excessive thirst, changes in taste, or dizziness. If any of these side effects worsen, it is important to consult your doctor.
Avoid consumption of alcohol while takingJardimet 5/500mg Tablet since it may increase the risk of lactic acidosis.
Jardimet 5/500mg Tablet is not recommended for use in pregnant women. Consult your doctor before taking Jardimet 5/500mg Tablet.
Jardimet 5/500mg Tablet is not recommended for use in breastfeeding women. Consult your doctor before taking Jardimet 5/500mg Tablet.
Do not drive or operate any tools or machines if you experience dizziness after taking Jardimet 5/500mg Tablet.
Jardimet 5/500mg Tablet is not recommended for use in patients with severe kidney disease. Consult your doctor before taking Jardimet 5/500mg Tablet.
Jardimet 5/500mg Tablet is not recommended for use in patients with liver problems. Consult your doctor before taking Jardimet 5/500mg Tablet.
Jardimet 5/500mg Tablet effectively reduces blood glucose levels, whereas empagliflozin acts by blocking the activity of a protein called sodium-glucose co-transporter 2, which is responsible for the tubular reabsorption of glucose into the bloodstream and metformin acts by reducing the amount of glucose released into the bloodstream by the liver, thus helps in reducing blood glucose levels.
Jardimet 5/500mg Tablet is used to treat type II diabetes mellitus in addition to diet and exercise among adults who remain unresponsive to therapy with either metformin alone or in combination with other antidiabetic medicines
Empagliflozin is a sodium-glucose co-transporter 2 inhibitor (SGLT2). The main transporter, SGLT2, is in charge of reabsorbing glucose from the kidney and reintroducing it into circulation. Empagliflozin decreases renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and therefore improves urine glucose excretion via inhibiting SGLT2.
Metformin Hydrochloride is an oral antihyperglycemic medication of the biguanide class that is used to treat type 2 diabetes. It reduces both basal and postprandial plasma glucose levels. It does not result in hypoglycemia. Metformin Hydrochloride reduces hepatic glucose synthesis, lowers intestinal glucose absorption, and increases insulin sensitivity by increasing peripheral glucose uptake and utilization.
The dosage of Jardimet 5/500mg Tablet should be determined individually based on its effectiveness and tolerability. It is recommended to take this combination twice daily with meals. To minimize gastrointestinal side effects associated with Metformin Hydrochloride, dose escalation should be done gradually.
The maximum recommended daily dose of Metformin Hydrochloride is 2000 mg, and for Empagliflozin, it is 25 mg.
Here are the recommended starting doses based on different scenarios:
Administration:
The risk of lactic acidosis may be increased when using inhibitors of carbonic anhydrase. It is advisable to conduct more frequent monitoring in such cases. Certain medications, such as Ranolazine, Vandetanib, dolutegravir, and Cimetidine, can reduce the clearance of Metformin Hydrochloride, leading to increased levels in the body. The potential benefits and risks of using these drugs together should be carefully considered.
Alcohol consumption can worsen Metformin Hydrochloride's effect on lactate metabolism, potentially increasing the risk of lactic acidosis. Patients should be cautioned about the hazards of excessive alcohol intake and advised to exercise caution.
It is important for healthcare professionals to be aware of these interactions and to inform patients about the potential risks associated with the concurrent use of certain medications and alcohol while taking Metformin Hydrochloride.
In individuals with moderate to severe renal impairment and End Stage Renal Disease, this combination is contraindicated (ESRD). It is also not recommended for patients who have metabolic acidosis, including diabetic ketoacidosis, or who have a history of severe hypersensitivity to Empagliflozin, Metformin Hydrochloride, or any of the excipients in this combination.
Inform pregnant women about the potential risk to their fetus, especially during the second and third trimesters. This is not advised if you are nursing.
Maintain a temperature of less than 30°C and keep it away from light and moisture. Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.